相关实验视频
Updated: May 5, 2026

07:33
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
23.1K
SCALA:一个随机的第一期试验,比较了在患有渐进性多发性硬化症的患者中,皮下和静脉注射的阿勒姆图祖马布
Xavier Montalban1, Breogan Rodriguez-Acevedo2, Carlos Nos2
1Vall d'Hebron University Hospital and Multiple Sclerosis Centre of Catalonia, Passeig Vall d'Hebron 119-129, Edifici Cemcat, Barcelona 08035, Spain.
Therapeutic advances in neurological disorders
|November 8, 2024
概括
皮下用阿勒姆图祖马布在进展性多发性硬化症中显示出与静脉注射相似的淋巴细胞枯竭和重新填充. 这种亚皮制剂的阿勒姆图祖马布显示了患者可控的安全性.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿拉姆图祖马布是复发性复发性多发性硬化症的已知静脉注射治疗方法.
- 有限的数据存在于subcutaneous管理的阿莱姆图祖马布.
研究的目的:
- 评估亚皮用阿勒姆图祖马布在进展性多发性硬化症中的药理学,药理动力学和安全性.
- 为了比较皮下阿勒姆图祖马布和静脉注射.
主要方法:
- 一期,开放标签,随机化研究 (SCALA) 涉及24名患有进展性多发性硬化症的参与者.
- 参与者接受了皮下 (SC) 或静脉注射 (IV) 阿拉姆图祖马布 (12 mg/天).
- 主要终点是CD3+淋巴细胞计数;次要终点包括PD和PK参数.
主要成果:
- 无论是SC还是IV的阿莱姆图祖马布都显示出显著的CD3+淋巴细胞枯竭和部分重新填充.
- 与IV相比,皮下用阿勒姆图祖马布的血清度较低 (32%的生物可用性).
- 没有任何不良事件导致永久性治疗中止或死亡.
结论:
- 皮下用阿勒姆图祖马布表现出与静脉注射相似的淋巴细胞枯竭和重新填充模式.
- 通过皮下注射的阿莱姆图祖马布具有可管理的安全性,没有新的安全问题.
- 观察到的神经结果的稳定表明阿勒姆图祖马布的潜在长期益处.
相关概念视频
Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Bioavailability Study Design: Single Versus Multiple Dose Studies
383
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
383
Bioavailability Study Design: Healthy Subjects Versus Patients
248
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
248
Multiple Sclerosis l: Introduction
20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20

